- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Uterine Leiomyoma Associated Pain Treated Effectively by Relugolix Combination Therapy - Video
Overview
A new study in Obstetrics & Gynecology journal points that Relugolix-CT was effective and significantly reduced moderate-to-severe uterine leiomyoma-associated pain with a more pronounced effect on menstrual pain.
The effect of once-daily relugolix combination therapy was assessed in a combination of relugolix-CT: relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg, compared with placebo on moderate-to-severe pain in women with uterine leiomyomas and heavy menstrual bleeding.
A multinational, double-blind, 24-week, randomized, phase 3 studies "LIBERTY 1 and 2" were conducted in premenopausal women with uterine leiomyoma–associated heavy menstrual bleeding. A predefined secondary objective was to determine the effect of Relugolix-CT on moderate-to-severe uterine leiomyoma–associated pain in the pain subpopulation. The key secondary endpoint was defined as the proportion of women achieving minimal-to-no uterine leiomyoma–associated pain at week 24; menstrual and nonmenstrual pain were evaluated in prespecified secondary analyses. Treatment comparisons were performed in the pooled LIBERTY 1 and 2 pain subpopulation using the Cochran-Mantel-Haenszel test stratified by baseline menstrual blood loss volume.
A total of 509 women were randomized from both trials to relugolix-CT or placebo. Of these, 277 (54.4%) met pain subpopulation requirements. With relugolix-CT, 45.2% of women achieved minimal-to-no pain compared with 13.9% with placebo. The proportions of women with minimal-to-no pain during menstrual days and during nonmenstrual days were significantly higher with relugolix-CT 65.0% and 44.6% compared with placebo 19.3% , and 21.6%.
Researchers concluded that over 24 weeks, relugolix-CT significantly reduced moderate-to- severe uterine leiomyoma–associated pain with a more pronounced effect on menstrual pain. These data support that relugolix-CT had clinically meaningful effects on women's experience of uterine leiomyoma–associated pain.
Speakers
Dr Priyanka Ahuja
MBBS- MAMC Delhi, MS(Obstetrics & Gynaecology)